Currently, CD19-directed CAR T-cell therapy is being explored particularly in the clinical management of B-cell malignancies including acute lymphoblastic leukemia (ALL) and non-Hodgkin lymphoma (NHL) [2]. The gene discussed is CD19; the disease is acute lymphoblastic leukemia.